XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2
Commitments and Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 48 Months Ended
Dec. 31, 2023
USD ($)
Nov. 09, 2022
USD ($)
Jun. 02, 2022
USD ($)
Jul. 31, 2024
Jul. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2013
USD ($)
Apr. 30, 2013
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2014
USD ($)
Aug. 21, 2022
USD ($)
Mar. 28, 2024
USD ($)
Aug. 21, 2023
USD ($)
Jun. 30, 2023
EUR (€)
Jul. 08, 2021
USD ($)
Aug. 31, 2019
USD ($)
Jul. 31, 2008
USD ($)
Feb. 28, 2005
USD ($)
Commitment And Contingencies [Line Items]                                        
Annual sales at the time of settlement                 $ 700,000,000                 $ 350,000,000    
Annual sales of Effexor                         $ 2,600,000,000              
Annual sales of Lamictal                                     $ 2,300,000,000 $ 950,000,000
Annual sales of Niaspan             $ 1,100,000,000 $ 416,000,000                        
Litigation settlement amount           $ 4,250,000,000                            
Litigation settlement amount awarded distribution period           13 years                            
Annual sales of Copaxone                       $ 373,000,000                
Generic modafinil, and imposed fines amount $ 4,771,000,000               4,730,000,000   $ 4,771,000,000         € 60.5        
Loss Contingency Accrual, Provision 235,500,000                                      
Annual sales of the time of settlement of viread                 582,000,000                      
Annual sales of the time of settlement of Truvada                 2,400,000,000                      
Annual sales of the time of settlement of Atripla                 2,900,000,000                      
Annual sales of the time of New launch of viread                 728,000,000                      
Annual sales of the time of New launch of Truvada                 2,100,000,000                      
Annual sales of the time of New launch of Atripla                 444,000,000                      
Litigation Settlement Amount Distributable In Kind                 1,200,000,000                      
Accrual for Environmental Loss Contingencies                 $ 300,000                      
Loss Contingencies On Environmental Laws Penalty                                 $ 1,400,000      
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement                 99.00%                      
Other commitment                           $ 150,000,000            
Annual Sales Of Revlimid                 $ 3,500,000,000                      
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer 300,000,000                                      
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population $ 1,000,000                                      
Percentage Of Share Of The National Population 1.00%                                      
Percentgae of amount in cash settlement                 20.00%                      
Litigation Settlement Amount Distributable in cash                 $ 240,000,000                      
Loss Contingency, Damages Awarded, Value   $ 176,500,000                                    
Maximum [Member]                                        
Commitment And Contingencies [Line Items]                                        
Damage claimed                     $ 1,000,000,000                  
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member]                                        
Commitment And Contingencies [Line Items]                                        
Other commitment                             $ 50,000,000          
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member]                                        
Commitment And Contingencies [Line Items]                                        
Other commitment, to be paid, year five                             135,000,000          
Other commitment to pay for each year                             22,500,000          
Other commitment                             $ 225,000,000          
Opioid Litigation [Member]                                        
Commitment And Contingencies [Line Items]                                        
Loss contingency accrual, product liability, undiscounted, to be paid, year five                 393,000,000                      
Loss contingency accrual, product liability, undiscounted, to be paid, year four                 374,000,000                      
Loss contingency accrual, product liability, undiscounted, to be paid, year three                 368,000,000                      
Loss contingency accrual, product liability, undiscounted, to be paid, year two                 364,000,000                      
Loss contingency accrual, product liability, undiscounted, to be paid, year one                 415,000,000                      
Modafinil Settlement Agreement [Member]                                        
Commitment And Contingencies [Line Items]                                        
Loss contingency aggregate payments paid                 $ 77,000,000                      
Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member]                                        
Commitment And Contingencies [Line Items]                                        
Litigation settlement amount     $ 420,000,000                                  
Litigation With US Hospitals And Other Healthcare Providers [Member]                                        
Commitment And Contingencies [Line Items]                                        
Litigation settlement amount         $ 126,000,000                              
Litigation settlement amount awarded distribution period       18 years                                
Product WAC Value         $ 49,000,000                              
Product WAC Term         7 years                              
Europe [Member]                                        
Commitment And Contingencies [Line Items]                                        
Damage claimed                   $ 50,000,000                    
Eosinophilic Esophagitis [Member]                                        
Commitment And Contingencies [Line Items]                                        
Damage claimed                   200,000,000                    
Eosinophilic Esophagitis [Member] | United States [Member]                                        
Commitment And Contingencies [Line Items]                                        
Damage claimed                   $ 150,000,000                    
AndroGel Rate at 1% [Member]                                        
Commitment And Contingencies [Line Items]                                        
Annual sales at the time of settlement                                   $ 140,000,000